Information intended for healthcare professionals only. This formulary decision guide was initiated, funded, and reviewed by Boehringer Ingelheim Limited and Lilly Diabetes Alliance. The format was developed by Guidelines in Practice. Prescribing information can be found on page 2 of the formulary decision guide.

Click here to download the formulary decision guide.

Click here to view prescribing information and adverse event reporting information.

If the PDF does not load within 5 seconds, please refresh the page.

UK/EMP/00431c

Date of preparation: May 2018